Prevalence of Premenstrual Syndrome in Women of Reproductive Age

Premenstrual Syndrome Clinical Trial

— Sd-Premens  

Official title:

Prevalence of Premenstrual Syndrome in Women of Reproductive Age

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06117215
• Other study ID #: 2023_RIPH_014_Sd-Premens
• Status: Not yet recruiting
• Start date: December 1, 2023
• Est. completion date: May 1, 2024

Study information

• Verified date: October 2023
• Source: Université de Reims Champagne-Ardenne
• Contact: Barbe Coralie
• Phone: 0326913665
• Email: coralie.barbe[@]univ-reims.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The menstrual cycle is a recurring process in the lives of women from puberty until menopause. This cycle can cause various discomforts, including premenstrual syndrome.

Described differently, premenstrual syndrome is a collection of physical and psychological symptoms that occur during the luteal phase of the menstrual cycle and subside upon the arrival of menstruation. This definition is conditioned by the existence of a free interval of at least one week between the end of the period and the appearance of these symptoms, as well as a global impairment of functioning and quality of life for women.

The impact on the personal, social, and professional lives of affected women, as well as the pain and discomfort it causes, may be perceived as insignificant or normal by women. Therefore, few women report the existence of these disorders to healthcare professionals. As the subject is not approached, these women are not taken care of even though therapeutic solutions could be proposed.

This pathology affects a large number of women, but its prevalence differs greatly depending on the studies conducted on the subject, suggesting a lack of knowledge of this syndrome.

Description:

The main aim is to describe the prevalence of premenstrual syndrome among women of reproductive age.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 2000
• Est. completion date: May 1, 2024
• Est. primary completion date: February 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• women in childbearing age, i.e., menstrual or secondary amenorrhoea, non-menopausal

• Over 18 years of age

• Agreeing to participate in the study

Exclusion Criteria:

• Menopause

• Having had a hysterectomy

• With primary amenorrhea

• Protected by law

• Refusing to participate in the study

Related Conditions & MeSH terms

• Premenstrual Syndrome
• Syndrome

Intervention

Other:
• Data collection
data collection

Locations

Country	Name	City	State
France	Ufr Medecine Urca	Reims

Sponsors (1)

Lead Sponsor	Collaborator
Université de Reims Champagne-Ardenne

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	premenstrual syndrome	Prevalence of premenstrual syndrome defined as a set of physical, psychic and behavioral symptoms, appearing in the luteal phase of the menstrual cycle (that is, in the days before menstruation) and yielding with them, conditioned by a sufficient severity to alter the overall functioning and quality of life of women and must be present over at least 2 consecutive cycles.	Day 0